A novel feedback loop: CELF1/circ-CELF1/BRPF3/KAT7 in cardiac fibrosis

Acta Pharmaceutica Sinica B

Available online 29 July 2025

Acta Pharmaceutica Sinica BAuthor links open overlay panel, , , , , , , , , , , , , , , , , , , …Abstract

Cardiac fibrosis is characterized by an elevated amount of extracellular matrix (ECM) within the heart. However, the persistence of cardiac fibrosis ultimately diminishes contractility and precipitates cardiac dysfunction. Circular RNAs (circRNAs) are emerging as important regulators of cardiac fibrosis. Here, we elucidate the functional role of a specific circular RNA CELF1 in cardiac fibrosis and delineate a novel feedback loop mechanism. Functionally, circ-CELF1 was involved in enhancing fibrosis-related markers' expression and promoting the proliferation of cardiac fibroblasts (CFs), thereby exacerbating cardiac fibrosis. Mechanistically, circ-CELF1 reduced the ubiquitination-degradation rate of BRPF3, leading to an elevation of BRPF3 protein levels. Additionally, BRPF3 acted as a modular scaffold for the recruitment of histone acetyltransferase KAT7 to facilitate the induction of H3K14 acetylation within the promoters of the Celf1 gene. Thus, the transcription of Celf1 was dramatically activated, thereby inhibiting the subsequent response of their downstream target gene Smad7 expression to promote cardiac fibrosis. Moreover, Celf1 further promoted Celf1 pre-mRNA transcription and back-splicing, thereby establishing a feedback loop for circ-CELF1 production. Consequently, a novel feedback loop involving CELF1/circ-CELF1/BRPF3/KAT7 was established, suggesting that circ-CELF1 may serve as a potential novel therapeutic target for cardiac fibrosis.

Graphical abstractThe schematic diagram illustrates a novel feedback loop involving CELF1/circ-CELF1/BRPF3/KAT7 in cardiac fibrosis pathogenesis.Image 1Download: Download high-res image (219KB)Download: Download full-size imageKeywords

CELF1

Circ-CELF1

Cardiac fibrosis

BRPF3

KAT7

Feedback loop

Histone acetylation

Therapeutic target

© 2025 The Author(s). Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

Comments (0)

No login
gif